MET is considered a strong candidate given its response to crizotinib, currently a treatment for ALK- and ROS1-rearranged lung cancers [14,25], however, MET alterations are uncommon, occurring in approximately 5% of NSCLC. This evidence concerns the gene MET and lung carcinoma.